Walmart to Pay $50 Million to Settle Allegations of Illegally Filling Invalid Opioid Prescriptions

Walmart agreed to a $50 million settlement for allegedly filling invalid opioid prescriptions. The Justice Department and DEA claimed Walmart's pharmacies and compliance team ignored red flags. Walmart will establish monitoring and reporting systems as part of the agreement.

Walmart will build a $1.3B, 1.5M sq ft automated fulfillment center in Georgia, its sixth such facility. The center will employ 1,000 workers and support ecommerce delivery. Walmart processes over 50% of ecommerce orders through automated facilities, according to the company. The center will reduce order fulfillment steps and increase productivity by 50%, per partner Knapp.

Walmart (WMT) reported Q2 revenue of $187.9B, up 5.9%, with e-Commerce sales rising 23% and advertising revenue up 38%. Operating income increased 17.4%, and gross margin expanded 96 bps. The company raised its FY 2027 outlook to 4%-5% sales growth and 7%-8.5% adjusted operating income growth. Bernstein maintains a 'Buy' rating with a $142 price target, citing strong growth in digital and advertising revenue.

Walmart settled a U.S. Justice Department lawsuit alleging unlawful opioid dispensing. The company was accused of filling invalid prescriptions and failing to report suspicious orders, contributing to the opioid crisis. Settlement details were not disclosed. The case followed a multiyear investigation, with potential fines of $67,627 per unlawful prescription and $15,691 per unreported order.

Walmart (WMT) reported Q2 revenue of $187.9B, with global e-commerce up 23% and advertising sales up 38%. E-commerce sales grew 24% in the US, and marketplace sales jumped 52%. Adjusted EPS rose to $0.81. Walmart raised full-year sales and earnings guidance. However, the stock trades at a premium, and cost pressures are building, with fuel costs expected to rise over $2B. US consumer confidence fell in August, and health and wellness sales subtracted from US comparable sales.

Walmart (WMT) reported 3.4% Q2 comparable sales growth, excluding pharmacy items, while Home Depot (HD) saw strength among budget-conscious DIYers. Both companies noted selective consumer spending. Walmart and Target saw smaller basket sizes, indicating cautious consumer behavior. Analysts highlight trade-down demand for Walmart and DIY substitution for Home Depot, but both face broader budget pressures.